stockportfolio.pro
Stocks / FDMT vs STRO
FDMT vs STRO
4D Molecular Therapeutics, Inc. and Sutro Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| 4D Molecular Therapeutics, Inc. (FDMT) | Sutro Biopharma, Inc. (STRO) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $85.21M | $102.48M |
| Net income (latest FY) | $-140.11M | $-191.09M |
| Revenue growth (5y CAGR) | 44.3% | 19.1% |
| Net margin | -164.4% | -186.5% |
| Return on equity | -27.7% | 144.3% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open FDMT — free Open STRO — freeFrequently asked questions
Which is bigger, FDMT or STRO?
Sutro Biopharma, Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, FDMT or STRO?
Over the last five fiscal years, 4D Molecular Therapeutics, Inc. grew revenue faster — 44.3%/yr versus 19.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.